Evidence map›Paper›PMID 38022677›Full record

ArticleFrontiers in immunology2023

Significance of NotchScore and JAG1 in predicting prognosis and immune response of low-grade glioma.

Bo Shi, Fei Ge, Liangliang Cai, Yi Yang, Xiaohui Guo, Rui Wu, Zhehao Fan, Binjie Cao, Ning Wang, Yue Si and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Bo Shi *Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Fei Ge *Department of Gastroenterology, Haian Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nantong, Jiangsu, China.
Liangliang Cai *Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Yi Yang *Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Xiaohui GuoSchool of Life Science, Liaoning Normal University, Dalian, Liaoning, China.
Rui WuSchool of Life Science, Liaoning Normal University, Dalian, Liaoning, China.
Zhehao FanInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Binjie CaoInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Ning WangInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Yue SiInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Xinyue LinInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Weibing DongSchool of Life Science, Liaoning Normal University, Dalian, Liaoning, China.
Haibo SunInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Yangzhou University · CNLiaoning Normal University · CNNanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Low-grade glioma (LGG) is a prevalent malignant tumor in the intracranial region. Despite the advancements in treatment methods for this malignancy over the past decade, significant challenges still persist in the form of drug resistance and tumor recurrence. The Notch signaling pathway plays essential roles in many physiological processes as well as in cancer development. However, the significance of the pathway and family genes in LGG are poorly understood. Methods: We conducted gene expression profiling analysis using the TCGA dataset to investigate the gene set associated with the Notch signaling pathway. we have proposed a metric called "NotchScore" that quantifies the strength of the Notch signaling pathway and enables us to assess its significance in predicting prognosis and immune response in LGG. We downregulated JAG1 in low-grade gliomas to assess its influence on the proliferation and migration of these tumors. Ultimately, we determined the impact of the transcription factor VDR on the transcription of PDL1 through chip-seq data analysis. Results: Our findings indicate that tumors with a higher NotchScore, exhibit poorer prognosis, potentially due to their ability to evade the anti-tumor effects of immune cells by expressing immune checkpoints. Among the genes involved in the Notch signaling pathway, JAG1 has emerged as the most representative in terms of capturing the characteristics of both NotchScore and Notch pathways. The experimental results demonstrate that silencing JAG1 yielded a significant decrease in tumor cell proliferation in LGG cell lines. Our study revealed mechanisms by which tumors evade the immune system through the modulation of PDL1 transcription levels via the PI3K-Akt signaling pathway. Additionally, JAG1 potentially influences PDL1 in LGG by regulating the PI3K-Akt signaling pathway and the expression of the transcription factor VDR. Discussion: These findings contribute to our understanding of immune evasion by tumors in LGG. The insights gained from this research may have implications for the development of therapeutic interventions for LGG.

Indexed as

GliomaPhosphatidylinositol 3-KinasesHumansImmunityJagged-1 ProteinNeoplasm Recurrence, LocalPrognosisProto-Oncogene Proteins c-aktTranscription FactorsJAG1 protein, humanJagged-1 ProteinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTranscription FactorsJAG1low-grade gliomanotchPDL1prognosistumor immune microenvironment

Identifiers

PMID38022677
PMCPMC10679421
OpenAlexW4388623675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.